Cognitive dysfunction in depression is a prevalent and debilitating symptom that is poorly treated by the currently available pharmacotherapies. Research over the past decade has provided evidence for proinflammatory involvement in the neurobiology of depressive disorders and symptoms associated with these disorders, including aspects of memory dysfunction. Recent clinical studies implicate inflammation-related changes in kynurenine metabolism as a potential pathogenic factor in the development of a range of depressive symptoms, including deficits in cognition and memory. Additionally, preclinical work has demonstrated a number of mood-related depressive-like behaviors to be dependent on indoleamine 2,3-dioxygenase-1 (IDO1), the inflammation-induced rate-limiting enzyme of the kynurenine pathway. Here, we demonstrate in a mouse model, that peripheral administration of endotoxin induced a deficit in recognition memory. Mice deficient in IDO were protected from cognitive impairment. Furthermore, endotoxin-induced inflammation increased kynurenine metabolism within the perirhinal/entorhinal cortices, brain regions which have been implicated in recognition memory. A single peripheral injection of kynurenine, the metabolic product of IDO1, was sufficient to induce a deficit in recognition memory in both control and IDO null mice. Finally, kynurenine monooxygenase (KMO) deficient mice were also protected from inflammation-induced deficits on novel object recognition. These data implicate IDO-dependent neurotoxic kynurenine metabolism as a pathogenic factor for cognitive dysfunction in inflammation-induced depressive disorders and a potential novel target for the treatment of these disorders.
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Introduction
Activation of the peripheral innate immune system and the production of proinflammatory cytokines are now recognized as important contributors to neuropsychiatric illnesses, specifically in the development of depressive symptoms including aspects of cognitive impairment (Reichenberg et al., 2001; Dantzer et al., 2008) . Depressed patients often exhibit increased plasma levels of proinflammatory cytokines compared to healthy controls including tumor necrosis factor (TNF)-a, interleukin (IL)-6, and IL-1b (Dantzer et al., 2008; Dowlati et al., 2010) . Further, administration of cytokines, like interferon (IFN)-a, for the treatment of some cancers and viral infections has been shown to induce symptoms of major depression in more than half of the patients undergoing treatment (Capuron and Miller, 2004) . More recently, the administration of bacterial endotoxin (lipopolysaccharide or LPS) has become a reliable experimental method to activate the peripheral immune system in both human and animal studies to explore the mediators linking a proinflammatory milieu to resultant depressive symptoms. A low dose of endotoxin in healthy human volunteers was sufficient to increase TNF-a and IL-6 plasma levels up to 4 h after administration which coincided with an increase in depressed mood and a decrease in memory functions in short term recall tests (Reichenberg et al., 2001) . Furthermore, in rodents, administration of moderate doses of LPS (<1.0 mg/kg) results in a characteristic sickness response including decreased food intake and reduced locomotion which subsides by approximately 12-18 h post-administration followed by the http://dx.doi.org/10.1016/j.bbi.2015.06.022 0889-1591/Published by Elsevier Inc.
